Mauna Kea Technologies Posts 68% Core Revenue Growth in Q1 2026
Event summary
- Q1 2026 core revenue grew 68% year-over-year to €1.53M, with U.S. sales up 34% and international sales surging 326%.
- Cellvizio system sales rose 85% in the U.S., with average prices exceeding $200K, while probe sales hit their highest Q1 since 2016.
- Company launched CellTolerance reference center in Southern California and added two new U.S. pay-per-use accounts.
- Regulatory clearances obtained in Switzerland and UK expected to drive immediate demand for Cellvizio.
The big picture
Mauna Kea Technologies' strong Q1 2026 performance reflects growing clinical adoption of Cellvizio, particularly for pancreatic cyst evaluation. The company's strategic focus on expanding its CellTolerance application internationally positions it to capitalize on unmet medical needs, though execution risks remain in scaling commercial activity. The 68% core revenue growth underscores the platform's increasing role in real-time cellular imaging across multiple medical specialties.
What we're watching
- U.S. Market Penetration
- How the launch of TaeWoong Medical USA sales and new pay-per-use accounts will affect Q2 revenue growth.
- International Expansion
- Whether the 326% international sales growth can be sustained as regulatory approvals materialize in new territories.
- CellTolerance Adoption
- The pace at which the CellTolerance application gains traction in key markets like Germany and the U.S.
Related topics